Why I’m backing ketamine for treatment-resistant depression
US psychiatrist on FDA expert panel says he voted with the majority to approve ketamine for the condition
Treatment-resistant depression affects one in three of the estimated 16.2 million adults in the US who have suffered at least one major depressive episode.
For them, two or more therapies have failed and the risk of suicide is much greater. It’s a grim prognosis.
